| Writing Group Member | Employment | Research Grant | Other Research Support | Speakers’ Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
|---|---|---|---|---|---|---|---|---|
| Matthew J. Feinstein | Northwestern University | AHA (research support)†; NIH (research support)† | None | None | None | None | None | None |
| Priscilla Y. Hsue | San Francisco General Hospital | NIH (grant support)†; Regeneron/Sanofi (study drug and placebo provided for trial)*; Novartis (study drug and placebo provided for trial)* | None | None | None | None | Gilead*; Merck* | None |
| Laura A. Benjamin | University of Liverpool Institute of Infection and Global Health | None | None | None | None | None | None | None |
| Gerald S. Bloomfield | Duke Clinical Research Institute, Duke Global Health Institute and Duke University Medical Center | NIH (research grant R01MD013493)* | None | None | None | None | None | None |
| Judith S. Currier | Center for AIDS Research and Education | NIH grant (steering committee of REPRIEVE trial)*; Theratechnologies (PI of clinical trial at UCLA, ended June 2018)* | None | None | None | None | None | None |
| Matthew S. Freiberg | Vanderbilt University | NIH (grants studying HIV and CVD)† | None | None | None | None | None | None |
| Steven K. Grinspoon | Massachusetts General Hospital | Gilead†; KOWA†; Navidea*; Theratechnologies* (all to institution); NIH (P30 Center Grant)† | None | None | None | None | Theratechnologies* | None |
| Jules Levin | National AIDS Treatment Advocacy Project | None | None | None | None | None | None | None |
| Chris T. Longenecker | Case Western Reserve University School of Medicine | Gilead Sciences (ISR)† | None | None | None | None | None | None |
| Wendy S. Post | Johns Hopkins University, Johns Hopkins Hospital | NIH (to Hopkins)† | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.